HomeCompareECML vs MRK

ECML vs MRK: Dividend Comparison 2026

ECML yields 1.26% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $9.3K in total portfolio value
10 years
ECML
ECML
● Live price
1.26%
Share price
$36.34
Annual div
$0.46
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.5K
Annual income
$137.23
Full ECML calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — ECML vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodECMLMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ECML + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ECML pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ECML
Annual income on $10K today (after 15% tax)
$107.46/yr
After 10yr DRIP, annual income (after tax)
$116.65/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, MRK beats the other by $691.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ECML + MRK for your $10,000?

ECML: 50%MRK: 50%
100% MRK50/50100% ECML
Portfolio after 10yr
$26.1K
Annual income
$543.77/yr
Blended yield
2.08%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

ECML
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ECML buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricECMLMRK
Forward yield1.26%3.25%
Annual dividend / share$0.46$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$21.5K$30.7K
Annual income after 10y$137.23$950.29
Total dividends collected$1.3K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ECML vs MRK ($10,000, DRIP)

YearECML PortfolioECML Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,826$126.43$11,192$351.54$366.00MRK
2$11,712$127.92$12,524$392.70$812.00MRK
3$12,661$129.34$14,015$438.65$1.4KMRK
4$13,678$130.67$15,682$489.96$2.0KMRK
5$14,768$131.93$17,547$547.23$2.8KMRK
6$15,935$133.12$19,632$611.16$3.7KMRK
7$17,184$134.24$21,963$682.53$4.8KMRK
8$18,523$135.30$24,571$762.18$6.0KMRK
9$19,955$136.29$27,486$851.08$7.5KMRK
10$21,489$137.23$30,745$950.29$9.3KMRK

ECML vs MRK: Complete Analysis 2026

ECMLStock

The fund is an actively managed exchange-traded fund (“ETF”) that seeks to achieve its investment objective by investing in U.S. equity securities that the sub-adviser believes are under-valued and under-appreciated by the market. The sub-adviser employs a quantitative and systematic approach to long-term investing. It is expected that the fund will generally hold 60 to 70 stocks that are selected from a universe that includes all publicly traded stocks listed on the New York Stock Exchange (“NYSE”) and the Nasdaq Market (“Nasdaq”).

Full ECML Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this ECML vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ECML vs SCHDECML vs JEPIECML vs OECML vs KOECML vs MAINECML vs JNJECML vs ABBVECML vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.